486 related articles for article (PubMed ID: 11904965)
1. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
Kubo O; Takakura K
Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
[TBL] [Abstract][Full Text] [Related]
2. Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody.
Kokunai T; Tamaki N; Matsumoto S
J Neurosurg; 1990 Dec; 73(6):901-8. PubMed ID: 2230972
[TBL] [Abstract][Full Text] [Related]
3. [Anti-TA226 human monoclonal antibody (ACA-11) against glioma].
Kokunai T
Nihon Rinsho; 2002 Jan; 60(1):100-6. PubMed ID: 11808318
[TBL] [Abstract][Full Text] [Related]
4. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
Lee Y; Bigner DD
Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
[TBL] [Abstract][Full Text] [Related]
5. [Experimental study on immunotherapy of meningeal gliomatosis with monoclonal antibody].
Yamashita Y; Takahashi H; Nakazawa S
No To Shinkei; 1993 Jan; 45(1):63-70. PubMed ID: 8476656
[TBL] [Abstract][Full Text] [Related]
6. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based immunotherapy for malignant gliomas.
Akasaki Y; Black KL; Yu JS
Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
[TBL] [Abstract][Full Text] [Related]
8. [Advances of BRM therapy of malignant brain tumors].
Nagai M
Gan To Kagaku Ryoho; 1991 Feb; 18(2):188-94. PubMed ID: 1992912
[TBL] [Abstract][Full Text] [Related]
9. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization.
Corsini E; Gelati M; Calatozzolo C; Alessandri G; Frigerio S; De Francesco M; Poiesi C; Parati E; Croci D; Boiardi A; Salmaggi A
Cancer Immunol Immunother; 2004 Nov; 53(11):955-62. PubMed ID: 15449042
[TBL] [Abstract][Full Text] [Related]
11. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies: prospects for specific immunotherapy for gliomas.
Nowak TP
Am J Clin Oncol; 1987 Aug; 10(4):278-80. PubMed ID: 3113229
[TBL] [Abstract][Full Text] [Related]
13. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab.
Glassy MC; Hagiwara H
Hum Antibodies; 2009; 18(4):127-37. PubMed ID: 19996527
[TBL] [Abstract][Full Text] [Related]
14. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
16. Tumor antigens in astrocytic gliomas.
Kurpad SN; Zhao XG; Wikstrand CJ; Batra SK; McLendon RE; Bigner DD
Glia; 1995 Nov; 15(3):244-56. PubMed ID: 8586461
[TBL] [Abstract][Full Text] [Related]
17. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.
Mitra S; Li G; Harsh GR
Neurosurg Clin N Am; 2010 Jan; 21(1):67-76. PubMed ID: 19944967
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for human glioma: innovative approaches and recent results.
Hussain SF; Heimberger AB
Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of local immunoresistance in glioma.
Albesiano E; Han JE; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
